Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IXPLORE: Vilobelimab (IFX-1) in ANCA-Associated Vasculitis
NCT03712345Phase 2Terminated
- Sponsor
- InflaRx
- Start
- Oct 2018
- Primary completion
- Sep 2020
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of vilobelimab in granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) (3 arms), sponsored by InflaRx. Primary endpoint: Number and Percentage of Participants With at Least One Treatment-Emergent Adverse Event at 24 weeks. Started Oct 2018; status: terminated.
02
Drugs
vilobelimab
03
Conditions
granulomatosis with polyangiitis (GPA)microscopic polyangiitis (MPA)
Beyond the preview
Go deeper on NCT03712345.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03712345.